1. BOD Australia Limited (ASX: BDA) is in the sector of consumer discretionary having a keen interest in the medical cannabis market. It has a wide range of product line including Pinpoint Bright Brains, Flexofytol etc.
In the recent financial performance for 1H FY19, the company’s revenue from ordinary activities came in at $1.07 million and the pcp revenue was reported at $725,228. The net loss for the period was reported at $2.78 million, increased from the pcp loss of $1.37 million. The net tangible assets grew from 4.64 cents per share to 9.2 cents per share.
In the March 2019 quarterly report, the company reported the expansion of cannabis and hemp-based product which is being supplied to the Lambert Initiative. The company also strengthened its management team after the appointment of ex-Blackmore’s executives Charles Altshuler as the head of finance. Sales for the period were reported at $252,000.
The market capitalisation of the company is A$20.12 million. The 52-week high was noted at A$0.715 and 52-week low of the stock has been noted at A$0.275 respectively. The last traded price of the stock is A$0.285 as on 3rd May 2019. The year till date return of the stock is negative at 25.64%
- Auscann Group Holdings Limited (ASX: AC8) is an ASX listed pharmaceutical company based in Australia. It produces high-quality cannabinoid medicines and is initially aiming at medications for neuropathic and chronic pain.
In the HFY19 financial results, the company reported revenue of A$466,305 up from the previous number of A$129,128 a year ago. The net loss for the period was reported at A$4.43 million which has reduced from the previously reported loss of A$4.82 million.
In the March 2019 quarterly report, the company announced Acquisition of Research & Development facility for $5.25 million. The company has also progressed in Latin America with first cultivation activity between DayaCann and Khiron Life Sciences. At the end of the quarter, the company had net cash of A$34.21 million.
The market capitalisation of the company is A$114.4 million. The 52-week high of the stock is noted at A$1.79 and 52-week low of the stock is at A$0.295 respectively. The last traded price of the stock is A$0.365 as of 3rd May 2019. The YTD return of the stock is at negative 40.48%.
- Atlas Pearls Limited (ASX: ATP) is an ASX listed consumer discretionary company. The company has positioned as one of the leaders in eco-pearling space on a global scale. It primarily engages in pearl farming and owns several pearl farms.
In 1HFY19 results, the company reported revenue of $6.6 million which is marginally up as compared to $6.34 million revenue reported in 1HFY18. The net profit stood at $418,050 which is a huge increase compared to the previously reported loss of 1.54 million a year ago. It also benefited by the forex gains up to $480,396 in the same period.
In the latest trading update for the half year ending December 2018, released on 16th January 2019 stated Like-for-like sales for the period grew by 3.3%, and a security incident of theft was reported at remote pearl farm resulted in the loss of unseeded shells.
The market capitalisation of the company is A$6.42 million. The 52-week high of the stock is A$0.026. The last traded price of the stock is A$0.014 as on 3rd May 2019. The YTD return stands at negative 6.25%
- Cann Group Limited (ASX: CAN) is a healthcare company, primarily working in the medical cannabis industry. In February 2017, it had received medicinal cannabis research permit, making it the first company, to obtain in the Australian region.
In the latest investors’ presentation, the management highlighted about the expansion plan leading to the purchase of Mildura site for $10.75m for construction of facility incorporating the world scale greenhouse & associated support areas. It also signed an offtake agreement with Aurora Cannabis Inc. to underpin the investment risk.
In the March 2019 quarterly report, the company announced the completion of a $250,000 investment in independent medicinal cannabis clinic group Emerald Clinics. On the outlook front, the company started production of resin for Victoria’s Department of Health and expects regular order in the future.
The market capitalisation of the company is A$333.89 million. The 52-week high of the stock was noted at A$3.88 and 52-week low was noted at A$1.525. The last traded price of the stock is A$2.390 as of 3rd May 2019. The year till date return of the stock was noted at 19.5%.
- Roto-Gro International Limited (ASX: RGI) is a medical cannabis company based in the Australian region, which concentrates on the production of cannabis. It has collaborated with Freshero Pty Ltd and Gibio Inc, and these new ventures will leverage RotoGro’s technologies to produce greater yields with lower operating costs.
The company’s 1HFY19 performance has been subdued as the reported revenue was down by 72% at $119,918 from the pcp revenue of $428,585. The net loss also has risen from $881,722 to $2.13 million in the same period. Consequently, loss per share also increased from 1.06 cents per share (cps) to 2.17 cps.
On 24th April 2019, the company announced the completion of share placement worth $3.58 million from institutional and sophisticated investors.
The market capitalisation of the company is A$23.21 million. The 52-week high of the stock was A$0.555 and the 52-week low of the stock was A$0.195. The last traded price of the stock is A$0.195 as of 3rd May 2019. The Year till date return of the stock is negative 37.88%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.